<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168024">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00910104</url>
  </required_header>
  <id_info>
    <org_study_id>05-04-048</org_study_id>
    <secondary_id>1R01FD003460-02</secondary_id>
    <nct_id>NCT00910104</nct_id>
  </id_info>
  <brief_title>Cholestasis Reversal: Efficacy of IV Fish Oil</brief_title>
  <acronym>Reversal</acronym>
  <official_title>Cholestasis Reversal: Efficacy of IV Fish Oil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark Puder</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Omegaven is effective in the treatment of
      parenteral nutrition associated liver disease (PNALD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether the omega-3 fatty acid emulsion
      (Omegaven), when used in lieu of the conventional soy-based fat emulsion (Intralipid), is
      effective in the treatment of parenteral nutrition associated liver disease (PNALD).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of parenteral administration of fish oil derived fat emulsion (Omegaven®) to reverse established parenteral nutrition associated liver disease</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Parenteral Nutrition Associated Liver Disease</condition>
  <condition>Short Bowel Syndrome</condition>
  <condition>Gastrointestinal Disease</condition>
  <arm_group>
    <arm_group_label>Omegaven</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g/kg/day for duration of study participation for all participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven®</intervention_name>
    <description>10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated</description>
    <arm_group_label>Omegaven</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients will be PN dependent (unable to meet nutritional needs solely by enteral
             nutrition) and are expected to require PN for at least another 30 days

          2. Patients considered eligible for study participation must have parenteral nutrition
             associated liver disease (PNALD) as defined as a direct bilirubin of U&gt;U 2 mg/dl or
             currently on Omegaven through another protocol. Other causes of liver disease should
             be excluded. A liver biopsy is not necessary for treatment.

          3. Direct bilirubin &gt; 2.0 mg/dl or already on Omegaven through another protocol

          4. Signed patient informed consent.

          5. The patient must have utilized standard therapies to prevent the progression of
             his/her liver disease including surgical treatment, cyclic PN, avoiding overfeeding,
             reduction/removal of copper and manganese from PN, advancement of enteral feeding,
             and the use of ursodiol (i..e., Actigall®).

        Exclusion Criteria:

          1. Pregnancy

          2. Other causes of chronic liver disease (Hepatitis C, biliary atresia, and alpha 1
             anti-trypsin deficiency,)

          3. Enrollment in any other clinical trial involving an investigational agent (unless
             approved by the designated physicians on the multidisciplinary team)

          4. The parent or guardian or child unwilling to provide consent or assent

        In rare instances, patients diagnosed with PNALD may later be found to have liver disease
        due to other causes in addition to the use of PN (i.e., inborn errors of metabolism, viral
        infections ). Such causes may not be known at the time of enrollment and will not preclude
        them from continuing in the study. For the sake of statistical analysis, however, these
        patients will be excluded although all data will be collected and reviewed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark Puder, MD, PhD</last_name>
    <email>mark.puder@childrens.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen Gura, PharmD</last_name>
    <email>kathleen.gura@childrens.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Puder, MD, PhD</last_name>
      <email>mark.puder@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Gura, PharmD</last_name>
      <email>kathleen.gura@childrens.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Puder, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathleen M Gura, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Jaksic, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher P Duggan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gura KM, Lee S, Valim C, Zhou J, Kim S, Modi BP, Arsenault DA, Strijbosch RA, Lopes S, Duggan C, Puder M. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008 Mar;121(3):e678-86. doi: 10.1542/peds.2007-2248.</citation>
    <PMID>18310188</PMID>
  </results_reference>
  <results_reference>
    <citation>Gura KM, Duggan CP, Collier SB, Jennings RW, Folkman J, Bistrian BR, Puder M. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006 Jul;118(1):e197-201.</citation>
    <PMID>16818533</PMID>
  </results_reference>
  <results_reference>
    <citation>Puder M, Valim C, Meisel JA, Le HD, de Meijer VE, Robinson EM, Zhou J, Duggan C, Gura KM. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009 Sep;250(3):395-402. doi: 10.1097/SLA.0b013e3181b36657.</citation>
    <PMID>19661785</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>May 20, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Mark Puder</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>PNALD</keyword>
  <keyword>Omegaven</keyword>
  <keyword>Parenteral Nutrition Associated Liver Disease</keyword>
  <keyword>Cholestasis</keyword>
  <keyword>Short Bowel Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Short Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
